<p>根据公司在最近向美国证券交易委员会提交的 13F 表格，阿穆迪在 Cencora, Inc.（纽约证券交易所代码：COR - 免费报告）的股份中增加了 9.8% 的持仓。该机构投资者在本季度购买了额外的 131,826 股后，持有该公司 1,470,536 股股票。在最近的报告期结束时，阿穆迪持有 Cencora 约 0.76% 的股份，价值 425,514,000 美元。</p>
<ul>
<li>在下跌市场中，标准普尔 500 指数的前三大赢家</li>
</ul>
<p>其他一些机构投资者最近也买卖了该公司的股票。Net Worth Advisory Group 在第一季度将其在 Cencora 的持仓增加了 1.4%。Net Worth Advisory Group 现在持有 2,645 股该公司的股票，价值 736,000 美元，此前在上个季度购买了额外的 36 股。Obermeyer Wealth Partners 在第一季度将其在 Cencora 的持仓增加了 1.3%。Obermeyer Wealth Partners 现在持有 2,724 股该公司的股票，价值 758,000 美元，此前在上个季度购买了额外的 36 股。Cromwell Holdings LLC 在第一季度将其在 Cencora 的持仓增加了 9.5%。Cromwell Holdings LLC 现在持有 450 股该公司的股票，价值 125,000 美元，此前在上个季度购买了额外的 39 股。Pinnacle Wealth Management Advisory Group LLC 在第一季度将其在 Cencora 的持仓增加了 2.7%。Pinnacle Wealth Management Advisory Group LLC 现在持有 1,565 股该公司的股票，价值 435,000 美元，此前在上个季度购买了额外的 41 股。最后，Private Trust Co. NA 在第一季度将其在 Cencora 的持仓增加了 2.5%。Private Trust Co. NA 现在持有 1,933 股该公司的股票，价值 538,000 美元，此前在上个季度购买了额外的 47 股。目前，97.52% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些股票分析师最近对 COR 股票发表了看法。Robert W. Baird 在 5 月 8 日的报告中将 Cencora 的目标价从 314.00 美元上调至 350.00 美元，并给予该股票 “跑赢大盘” 的评级。花旗集团在 5 月 8 日的报告中将 Cencora 的目标价从 330.00 美元上调至 355.00 美元，并给予该股票 “买入” 的评级。富国银行在 8 月 13 日的报告中将 Cencora 的目标价从 337.00 美元上调至 354.00 美元，并给予该股票 “增持” 的评级。杰富瑞金融集团在 6 月 30 日的报告中将 Cencora 的目标价从 275.00 美元上调至 300.00 美元，并给予该股票 “持有” 的评级。最后，摩根士丹利在 7 月 16 日的报告中设定了 Cencora 的目标价为 330.00 美元，并给予该股票 “等权重” 的评级。九位研究分析师对该股票给予了 “买入” 评级，三位分析师给予了 “持有” 评级。根据 MarketBeat 的数据，Cencora 目前的平均评级为 “适度买入”，共识目标价为 311.25 美元。</p>
<ul>
<li>Walgreens 股票反弹：WBA 可能成为强劲买入的四个理由</li>
</ul>
<p><strong>查看我们对 COR 的最新分析</strong></p>
<h2>内部人士买卖</h2>
<p>在相关消息中，首席执行官 Robert P. Mauch 在 7 月 18 日星期五出售了 4,968 股公司的股票。该股票以平均价格 294.11 美元出售，总价值为 1,461,138.48 美元。出售后，首席执行官直接持有公司 42,351 股股票，价值 12,455,852.61 美元。这笔交易代表其持仓减少了 10.50%。该交易在向证券交易委员会的法律文件中披露，相关信息可通过此链接获取。此外，董事长 Steven H. Collis 在 7 月 22 日星期二出售了 14,578 股 Cencora 股票。该股票以平均价格 292.67 美元出售，总价值为 4,266,543.26 美元。交易后，董事长持有公司 309,913 股股票，价值约 90,702,237.71 美元。这笔交易代表其持股减少了 4.49%。该出售的披露信息可以在这里找到。内部人士在上个季度共出售了 34,125 股公司股票，价值 9,993,789 美元。内部人士持有公司 10.80% 的股票。</p>
<h2>Cencora 价格表现</h2>
<ul>
<li>Teva Pharma 是参与仿制药重新崛起的方式</li>
</ul>
<p>COR 股票在星期四开盘价为 294.82 美元。该公司的债务与股本比率为 3.64，速动比率为 0.53，流动比率为 0.90。Cencora, Inc.的 1 年最低价为 218.65 美元，1 年最高价为 309.35 美元。该公司的市值为 571.6 亿美元，市盈率为 30.33，市盈增长比率为 1.38，贝塔值为 0.62。该股票的 50 日简单移动平均线为 293.06 美元，200 日简单移动平均线为 282.92 美元。</p>
<p>Cencora（纽约证券交易所代码：COR - 获取免费报告）最近在 8 月 6 日发布了其财报。该公司报告本季度每股收益（EPS）为 4.00 美元，超出分析师一致预期的 3.79 美元，超出幅度为 0.21 美元。Cencora 的股本回报率为 267.36%，净利润率为 0.60%。该公司本季度的收入为 806.6 亿美元，而分析师预期为 803.4 亿美元。去年同期，该公司每股收益为 3.34 美元。该公司本季度的收入较去年同期增长了 8.7%。分析师预测 Cencora, Inc.在当前财年将发布 15.37 美元的每股收益。</p>
<h2>Cencora 股息公告</h2>
<p>该公司最近还宣布了季度股息，将于 9 月 3 日星期三支付。8 月 15 日星期五的登记股东获得每股 0.55 美元的股息。这相当于每年 2.20 美元的股息和 0.7% 的股息收益率。除息日期为 8 月 15 日星期五。Cencora 的股息支付比率目前为 22.63%。</p>
<h2>关于 Cencora</h2>
<p>（免费报告）</p>
<p>Cencora, Inc. 负责药品的采购和分销。该公司的美国医疗解决方案部门向急性护理医院和健康系统、独立和连锁零售药房、邮购药房、医疗诊所、长期护理和替代场所药房及其他客户分销药品、非处方医疗产品、家庭医疗用品和设备及相关服务；提供药房管理、人员配置和其他咨询服务；向零售和机构医疗提供者提供供应管理软件；向各种机构和零售医疗提供者提供包装解决方案；提供临床试验支持、产品上市后和商业化支持服务；为生物技术和制药制造商提供数据分析、结果研究和其他服务；向伴侣动物和生产动物市场提供药品、疫苗、驱虫剂、诊断产品、微饲料成分及其他产品；以及向制造商提供销售团队服务。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Cencora</li>
<li>何时出售股票以获利或止损</li>
<li>开学购物达到 400 亿美元：现在值得关注的三只零售股票</li>
<li>便士股票适合你的投资组合吗？</li>
<li>Alphabet 股票在躲避严厉的反垄断措施后大幅上涨</li>
<li>三只值得购买的医疗保健分红股票</li>
<li>为什么高通在经历数月滞后后表现优于 NVIDIA</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Cencora 吗？</h2>
<p>在考虑 Cencora 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而 Cencora 并不在名单上。</p>
<p>虽然 Cencora 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>阿穆迪在第一季度将其在 Cencora, Inc.（纽约证券交易所代码：COR）的持股比例提高了 9.8%，目前持有 1,470,536 股，价值 4.255 亿美元。其他机构投资者也增加了他们的持仓。分析师们为 Cencora 设定了价格目标，其中罗伯特·W·贝尔德为 350 美元，花旗集团为 355 美元。公司内部人士进行了股票出售，首席执行官罗伯特·P·毛赫和董事长史蒂文·H·科利斯出售了股份。Cencora 的股票开盘价为 294.82 美元，市值为 571.6 亿美元，市盈率反映了其财务表现</p>

<p>Amundi boosted its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 9.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,470,536 shares of the company's stock after purchasing an additional 131,826 shares during the quarter. Amundi owned approximately 0.76% of Cencora worth $425,514,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根据公司在最近向美国证券交易委员会提交的 13F 表格，阿穆迪在 Cencora, Inc.（纽约证券交易所代码：COR - 免费报告）的股份中增加了 9.8% 的持仓。该机构投资者在本季度购买了额外的 131,826 股后，持有该公司 1,470,536 股股票。在最近的报告期结束时，阿穆迪持有 Cencora 约 0.76% 的股份，价值 425,514,000 美元。</p>
</div><ul>
<li>Top 3 S&amp;P 500 Winners in a Losing Market</li>
</ul>
<div class="lb-trans"><ul>
<li>在下跌市场中，标准普尔 500 指数的前三大赢家</li>
</ul>
</div><p>A number of other institutional investors also recently bought and sold shares of the company. Net Worth Advisory Group boosted its position in Cencora by 1.4% during the first quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock worth $736,000 after purchasing an additional 36 shares in the last quarter. Obermeyer Wealth Partners boosted its position in Cencora by 1.3% during the first quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company's stock worth $758,000 after purchasing an additional 36 shares in the last quarter. Cromwell Holdings LLC boosted its position in Cencora by 9.5% during the first quarter. Cromwell Holdings LLC now owns 450 shares of the company's stock worth $125,000 after purchasing an additional 39 shares in the last quarter. Pinnacle Wealth Management Advisory Group LLC raised its holdings in shares of Cencora by 2.7% in the first quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,565 shares of the company's stock worth $435,000 after acquiring an additional 41 shares during the last quarter. Finally, Private Trust Co. NA raised its holdings in shares of Cencora by 2.5% in the first quarter. Private Trust Co. NA now owns 1,933 shares of the company's stock worth $538,000 after acquiring an additional 47 shares during the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也买卖了该公司的股票。Net Worth Advisory Group 在第一季度将其在 Cencora 的持仓增加了 1.4%。Net Worth Advisory Group 现在持有 2,645 股该公司的股票，价值 736,000 美元，此前在上个季度购买了额外的 36 股。Obermeyer Wealth Partners 在第一季度将其在 Cencora 的持仓增加了 1.3%。Obermeyer Wealth Partners 现在持有 2,724 股该公司的股票，价值 758,000 美元，此前在上个季度购买了额外的 36 股。Cromwell Holdings LLC 在第一季度将其在 Cencora 的持仓增加了 9.5%。Cromwell Holdings LLC 现在持有 450 股该公司的股票，价值 125,000 美元，此前在上个季度购买了额外的 39 股。Pinnacle Wealth Management Advisory Group LLC 在第一季度将其在 Cencora 的持仓增加了 2.7%。Pinnacle Wealth Management Advisory Group LLC 现在持有 1,565 股该公司的股票，价值 435,000 美元，此前在上个季度购买了额外的 41 股。最后，Private Trust Co. NA 在第一季度将其在 Cencora 的持仓增加了 2.5%。Private Trust Co. NA 现在持有 1,933 股该公司的股票，价值 538,000 美元，此前在上个季度购买了额外的 47 股。目前，97.52% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities analysts have recently weighed in on COR shares. Robert W. Baird boosted their price target on Cencora from $314.00 to $350.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday, May 8th. Citigroup boosted their price target on Cencora from $330.00 to $355.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, May 8th. Wells Fargo &amp; Company boosted their price target on Cencora from $337.00 to $354.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, August 13th. Jefferies Financial Group boosted their price target on Cencora from $275.00 to $300.00 and gave the stock a &#34;hold&#34; rating in a report on Monday, June 30th. Finally, Morgan Stanley set a $330.00 price target on Cencora and gave the stock an &#34;equal weight&#34; rating in a report on Wednesday, July 16th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Cencora currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $311.25.</p>
<div class="lb-trans"><p>一些股票分析师最近对 COR 股票发表了看法。Robert W. Baird 在 5 月 8 日的报告中将 Cencora 的目标价从 314.00 美元上调至 350.00 美元，并给予该股票 “跑赢大盘” 的评级。花旗集团在 5 月 8 日的报告中将 Cencora 的目标价从 330.00 美元上调至 355.00 美元，并给予该股票 “买入” 的评级。富国银行在 8 月 13 日的报告中将 Cencora 的目标价从 337.00 美元上调至 354.00 美元，并给予该股票 “增持” 的评级。杰富瑞金融集团在 6 月 30 日的报告中将 Cencora 的目标价从 275.00 美元上调至 300.00 美元，并给予该股票 “持有” 的评级。最后，摩根士丹利在 7 月 16 日的报告中设定了 Cencora 的目标价为 330.00 美元，并给予该股票 “等权重” 的评级。九位研究分析师对该股票给予了 “买入” 评级，三位分析师给予了 “持有” 评级。根据 MarketBeat 的数据，Cencora 目前的平均评级为 “适度买入”，共识目标价为 311.25 美元。</p>
</div><ul>
<li>Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>Walgreens 股票反弹：WBA 可能成为强劲买入的四个理由</li>
</ul>
</div><p><strong>View Our Latest Analysis on COR</strong></p>
<div class="lb-trans"><p><strong>查看我们对 COR 的最新分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In related news, CEO Robert P. Mauch sold 4,968 shares of the firm's stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $294.11, for a total value of $1,461,138.48. Following the sale, the chief executive officer directly owned 42,351 shares in the company, valued at $12,455,852.61. This trade represents a 10.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $292.67, for a total value of $4,266,543.26. Following the transaction, the chairman owned 309,913 shares in the company, valued at approximately $90,702,237.71. This trade represents a 4.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,125 shares of company stock worth $9,993,789 over the last quarter. Insiders own 10.80% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 Robert P. Mauch 在 7 月 18 日星期五出售了 4,968 股公司的股票。该股票以平均价格 294.11 美元出售，总价值为 1,461,138.48 美元。出售后，首席执行官直接持有公司 42,351 股股票，价值 12,455,852.61 美元。这笔交易代表其持仓减少了 10.50%。该交易在向证券交易委员会的法律文件中披露，相关信息可通过此链接获取。此外，董事长 Steven H. Collis 在 7 月 22 日星期二出售了 14,578 股 Cencora 股票。该股票以平均价格 292.67 美元出售，总价值为 4,266,543.26 美元。交易后，董事长持有公司 309,913 股股票，价值约 90,702,237.71 美元。这笔交易代表其持股减少了 4.49%。该出售的披露信息可以在这里找到。内部人士在上个季度共出售了 34,125 股公司股票，价值 9,993,789 美元。内部人士持有公司 10.80% 的股票。</p>
</div><h2>Cencora Price Performance</h2>
<div class="lb-trans"><h2>Cencora 价格表现</h2>
</div><ul>
<li>Teva Pharma is the way to play the re-rise of generic drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharma 是参与仿制药重新崛起的方式</li>
</ul>
</div><p>COR stock opened at $294.82 on Thursday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $309.35. The firm has a market cap of $57.16 billion, a P/E ratio of 30.33, a price-to-earnings-growth ratio of 1.38 and a beta of 0.62. The stock has a 50-day simple moving average of $293.06 and a 200-day simple moving average of $282.92.</p>
<div class="lb-trans"><p>COR 股票在星期四开盘价为 294.82 美元。该公司的债务与股本比率为 3.64，速动比率为 0.53，流动比率为 0.90。Cencora, Inc.的 1 年最低价为 218.65 美元，1 年最高价为 309.35 美元。该公司的市值为 571.6 亿美元，市盈率为 30.33，市盈增长比率为 1.38，贝塔值为 0.62。该股票的 50 日简单移动平均线为 293.06 美元，200 日简单移动平均线为 282.92 美元。</p>
</div><p>Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business had revenue of $80.66 billion during the quarter, compared to analyst estimates of $80.34 billion. During the same quarter last year, the firm earned $3.34 earnings per share. The company's revenue for the quarter was up 8.7% compared to the same quarter last year. On average, equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Cencora（纽约证券交易所代码：COR - 获取免费报告）最近在 8 月 6 日发布了其财报。该公司报告本季度每股收益（EPS）为 4.00 美元，超出分析师一致预期的 3.79 美元，超出幅度为 0.21 美元。Cencora 的股本回报率为 267.36%，净利润率为 0.60%。该公司本季度的收入为 806.6 亿美元，而分析师预期为 803.4 亿美元。去年同期，该公司每股收益为 3.34 美元。该公司本季度的收入较去年同期增长了 8.7%。分析师预测 Cencora, Inc.在当前财年将发布 15.37 美元的每股收益。</p>
</div><h2>Cencora Dividend Announcement</h2>
<div class="lb-trans"><h2>Cencora 股息公告</h2>
</div><p>The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora's dividend payout ratio is presently 22.63%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度股息，将于 9 月 3 日星期三支付。8 月 15 日星期五的登记股东获得每股 0.55 美元的股息。这相当于每年 2.20 美元的股息和 0.7% 的股息收益率。除息日期为 8 月 15 日星期五。Cencora 的股息支付比率目前为 22.63%。</p>
</div><h2>About Cencora</h2>
<div class="lb-trans"><h2>关于 Cencora</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.</p>
<div class="lb-trans"><p>Cencora, Inc. 负责药品的采购和分销。该公司的美国医疗解决方案部门向急性护理医院和健康系统、独立和连锁零售药房、邮购药房、医疗诊所、长期护理和替代场所药房及其他客户分销药品、非处方医疗产品、家庭医疗用品和设备及相关服务；提供药房管理、人员配置和其他咨询服务；向零售和机构医疗提供者提供供应管理软件；向各种机构和零售医疗提供者提供包装解决方案；提供临床试验支持、产品上市后和商业化支持服务；为生物技术和制药制造商提供数据分析、结果研究和其他服务；向伴侣动物和生产动物市场提供药品、疫苗、驱虫剂、诊断产品、微饲料成分及其他产品；以及向制造商提供销售团队服务。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Cencora</li>
<li>When to Sell a Stock for Profit or Loss</li>
<li>Back-to-School Shopping Hits $40B: 3 Retail Stocks to Watch Now</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Alphabet Stock Surges After Dodging Harsh Antitrust Remedies</li>
<li>3 Healthcare Dividend Stocks to Buy</li>
<li>Why Qualcomm Is Outperforming NVIDIA After Months of Lagging</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Cencora</li>
<li>何时出售股票以获利或止损</li>
<li>开学购物达到 400 亿美元：现在值得关注的三只零售股票</li>
<li>便士股票适合你的投资组合吗？</li>
<li>Alphabet 股票在躲避严厉的反垄断措施后大幅上涨</li>
<li>三只值得购买的医疗保健分红股票</li>
<li>为什么高通在经历数月滞后后表现优于 NVIDIA</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=COR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cencora Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cencora 吗？</h2>
</div><p>Before you consider Cencora, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Cencora 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而 Cencora 并不在名单上。</p>
</div><p>While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cencora 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

安本提升了在 Cencora, Inc. $COR 的持仓